![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/docs/US/2019-01-01/US10167290B2/abs.jpg.600x600.jpg)
- 专利标题： Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
-
申请号： US15680688申请日： 2017-08-18
-
公开(公告)号： US10167290B2公开(公告)日： 2019-01-01
- 发明人: Jan Elsner , Roy L. Harris , Branden Gingsee Lee , Deborah Mortensen , Garrick K. Packard , Patrick Papa , Jason Parnes , Sophie Perrin-Ninkovic , Jennifer Riggs , John Sapienza , Graziella I. Shevlin , Lida Tehrani , Jingjing Zhao
- 申请人： SIGNAL PHARMACEUTICALS, LLC
- 申请人地址： US CA San Diego
- 专利权人： Signal Pharmaceuticals, LLC
- 当前专利权人： Signal Pharmaceuticals, LLC
- 当前专利权人地址： US CA San Diego
- 代理机构： Jones Day
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; C07D498/14 ; C07D241/20 ; C07D471/04 ; C07D471/14 ; C07D487/10 ; C07D487/14
![Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors](/abs-image/US/2019/01/01/US10167290B2/abs.jpg.150x150.jpg)
摘要：
Provided herein are methods for the preparation of substituted pyrazino[2,3-b]pyrazines of the formula (II): the method comprising contacting a compound of formula (VI): with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R3, Y, the palladium catalyst and the base are as defined herein.
公开/授权文献
信息查询
